Neuroprotective therapeutics for Alzheimer's disease: progress and prospects - PubMed (original) (raw)
Review
Neuroprotective therapeutics for Alzheimer's disease: progress and prospects
Alan M Palmer. Trends Pharmacol Sci. 2011 Mar.
Abstract
The number of people with Alzheimer's disease (AD) has never been greater and is set to increase substantially in the decades ahead as the proportion of the population aged 65 years or more rises sharply. There is therefore an urgent need for safe and effective pharmacotherapy to help combat the corresponding and substantial increase in disease burden. Increased understanding of disease aetiology and pathophysiology, particularly in relation to the loss of vulnerable neurons and the formation of plaques and tangles, has increased hope for medications that can slow (or perhaps even halt) the course of the disease. In this article I review the neurobiological basis of AD, current progress towards neuroprotective therapeutics, and prospects for the future.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
- Pharmacotherapy for Alzheimer's disease: progress and prospects.
Palmer AM. Palmer AM. Trends Pharmacol Sci. 2002 Sep;23(9):426-33. doi: 10.1016/s0165-6147(02)02056-4. Trends Pharmacol Sci. 2002. PMID: 12237155 Review. - The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
Hardy J, Selkoe DJ. Hardy J, et al. Science. 2002 Jul 19;297(5580):353-6. doi: 10.1126/science.1072994. Science. 2002. PMID: 12130773 Review. - Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology.
Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F. Silvestrelli G, et al. Mech Ageing Dev. 2006 Feb;127(2):148-57. doi: 10.1016/j.mad.2005.09.018. Epub 2005 Nov 8. Mech Ageing Dev. 2006. PMID: 16278007 Review. - Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.
Shin J. Shin J. Int J Geriatr Psychiatry. 2011 May;26(5):546-8. doi: 10.1002/gps.2543. Int J Geriatr Psychiatry. 2011. PMID: 21446001 No abstract available. - Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease.
Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Gómez-Isla T, et al. Ann Neurol. 1997 Jan;41(1):17-24. doi: 10.1002/ana.410410106. Ann Neurol. 1997. PMID: 9005861
Cited by
- One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug.
Hughes RE, Nikolic K, Ramsay RR. Hughes RE, et al. Front Neurosci. 2016 Apr 25;10:177. doi: 10.3389/fnins.2016.00177. eCollection 2016. Front Neurosci. 2016. PMID: 27199640 Free PMC article. Review. - Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.
Robichaux WG 3rd, Cheng X. Robichaux WG 3rd, et al. Physiol Rev. 2018 Apr 1;98(2):919-1053. doi: 10.1152/physrev.00025.2017. Physiol Rev. 2018. PMID: 29537337 Free PMC article. Review. - Multi-modal latent space inducing ensemble SVM classifier for early dementia diagnosis with neuroimaging data.
Zhou T, Thung KH, Liu M, Shi F, Zhang C, Shen D. Zhou T, et al. Med Image Anal. 2020 Feb;60:101630. doi: 10.1016/j.media.2019.101630. Epub 2019 Dec 28. Med Image Anal. 2020. PMID: 31927474 Free PMC article. - Implication of the cooking oil-peroxidation product "hydroxynonenal" for Alzheimer's disease.
Yamashima T, Seike T, Mochly-Rosen D, Chen CH, Kikuchi M, Mizukoshi E. Yamashima T, et al. Front Aging Neurosci. 2023 Aug 25;15:1211141. doi: 10.3389/fnagi.2023.1211141. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37693644 Free PMC article. Review. - Protein Assemblies: Nature-Inspired and Designed Nanostructures.
Hamley IW. Hamley IW. Biomacromolecules. 2019 May 13;20(5):1829-1848. doi: 10.1021/acs.biomac.9b00228. Epub 2019 Apr 4. Biomacromolecules. 2019. PMID: 30912925 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical